Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung

被引:7
|
作者
Qiong, Zhao [1 ]
Na, Wang Yi [1 ]
Bo, Wang [2 ]
Zhu, Zeng [1 ]
Ling, Peng [1 ]
Bo, Mou Hai [1 ]
Min, Tang Ye [1 ]
Lei, Zeng [1 ]
Na, Hu Dan [1 ]
Bo, Zhao [1 ]
Fang, Liu Jun [1 ]
Seng, Zheng Shu [3 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Thorac Oncol Dept, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Hepatobiliary & Pancreat Surg Dept, Hangzhou 310003, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Non-small cell lung cancer; Squamous cell carcinoma; Smoking; EGFR; PIK3CA; ALK; NEVER-SMOKERS; PIK3CA MUTATIONS; CANCER PATIENTS; ADENOCARCINOMA; MARKERS; WOMEN;
D O I
10.1016/j.lungcan.2014.11.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Female patients with squamous cell carcinomas of the lung (SQCLC) in China differ from male patients in that most females are life-long never/light smokers. We hypothesized that the clinical characteristics and mutation profiles of a spectrum of driver genes in Chinese female patients with advanced SQCLC would also differ from those of male patients. Patients and methods: We examined the pathological subtype of SQCLC retrospectively by immunohistochemistry (IHC) and screened 38 female and 40 male patients with IIIB/IV-stage SQCLC in China from 2009 to 2012. Mutation analyses of EGFR, PIK3CA, KRAS, and PTEN were performed using PCR-based DNA sequencing. FGFR1 amplification and ALK rearrangements were detected by fluorescent in situ hybridization (FISH). A Cox regression model was used to assess the association between clinical features and genomic mutation status. Results: There were significantly fewer female patients with a history of smoking than males (5.3% vs. 90%; P < 0.001). A younger average age at diagnosis (54.5 vs. 61 years; P = 0.032) and a higher percentage of peripheral-type disease (47.4% vs. 25.0%; P = 0.040) were observed in females. No difference in ECOG score, tumor size, metastatic status, or overall survival between females and males was seen. PIK3CA mutations were significantly less common in female patients than males (0/38 vs. 6/40; P = 0.026). However, no significant difference in the mutational frequencies of EGFR, KRAS, PTEN, ALK, or FGFR1 was observed between females and males. Conclusions: Our data demonstrated that female patients with SQCLC are apparently a subtype, with a significantly lower percentage having a smoking history, a younger average age at diagnosis, a higher percentage of peripheral-type disease on radiological presentation, and a lower frequency of PIK3CA mutations. Given the similar survival outcomes between the genders, whether it is a distinct disease entity needs to be studied further in larger populations. (C)2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:117 / 121
页数:5
相关论文
共 50 条
  • [21] Driver and targetable alterations in Chinese patients with small bowel carcinoma
    Li, Jun
    Li, Xiaomo
    Dong, Ningning
    Yan, Shu
    Jing, Chao
    Ma, Tonghui
    Li, Wei
    Zhang, Chenghai
    Cai, Yi
    Deng, Wei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 6139 - 6150
  • [22] Driver and targetable alterations in Chinese patients with small bowel carcinoma
    Jun Li
    Xiaomo Li
    Ningning Dong
    Shu Yan
    Chao Jing
    Tonghui Ma
    Wei Li
    Chenghai Zhang
    Yi Cai
    Wei Deng
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 6139 - 6150
  • [23] Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
    Lu, Shun
    Li, Wei
    Zhou, Caicun
    Hu, Cheng-Ping
    Qin, Shukui
    Cheng, Gang
    Feng, Jifeng
    Wang, Jie
    Cseh, Agnieszka
    Peil, Barbara
    Gibson, Neil
    Ehrnrooth, Eva
    Zhang, Li
    ONCOTARGETS AND THERAPY, 2018, 11 : 8565 - 8573
  • [24] Cost-effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma
    Zhang, Li
    Su, Henghai
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Yan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [25] Metastatic squamous cell carcinoma of the lung to the conus medullaris
    Rivero-Garvia, Monica
    Rodriguez Boto, Gregorio
    NEUROLOGY INDIA, 2011, 59 (04) : 166 - 167
  • [26] Identification of genetic alterations in Chinese squamous cell lung carcinomas
    Shi, Y.
    Tao, D.
    Han, X.
    Yang, S.
    Wu, D.
    Song, W.
    Zhang, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S600 - S600
  • [27] Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study
    Yang, Jinhua
    Li, Yuping
    Ma, Benting
    Xie, Huikang
    Chen, Linsong
    Gao, Xuejuan
    He, Wenxin
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (12) : 7562 - +
  • [28] Comprehensive genomic profiling in Chinese patients with lung squamous cell carcinoma.
    Lian, Zuping
    Li, Heng
    Lei, Youming
    Xian, Lei
    Bu, Kunpeng
    Wang, Xiangping
    Chen, Zhonghai
    Guo, Honglin
    Chen, Xiaoqian
    Guo, Fei
    Zhang, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients
    Pan, Lulu
    Wang, Xijun
    Yang, Longhai
    Zhao, Lei
    Zhai, Linhui
    Xu, Junyu
    Yang, Yikun
    Mao, Yousheng
    Cheng, Shujun
    Xiao, Ting
    Tan, Minjia
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [30] Correlation of tumor immune microenvironment status and driver genes alterations in Chinese non-small-cell lung cancer patients.
    Guo, Jindong
    Xiong, Liwen
    Yuan, Haibin
    Hu, Mengna
    Zhang, Bei
    Zhang, Ding
    CANCER RESEARCH, 2022, 82 (12)